Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2006 Feb 15;16(4):1028-31. Epub 2005 Nov 8.

Conversion of potent MMP inhibitors into selective TACE inhibitors.

Author information

1
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000, USA. robert.cherney@bms.com

Abstract

Novel sultam hydroxamates with potent MMP activity were transformed into potent TACE inhibitors, lacking MMP activity. To accomplish this we relied on structural differences between the MMP and TACE S1' pockets and the known advantageous fit of a 2-methyl-4-quinolinylmethoxyphenyl group into this region. From this approach, compound 7d was identified as a potent TACE inhibitor (IC50 = 3.7 nM) that lacked MMP-1, -2, -9, and -13 activity.

PMID:
16289878
DOI:
10.1016/j.bmcl.2005.10.078
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center